Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Overview

This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases. The primary objective is to evaluate the relative change from baseline in response markers related to bone metabolism (alkaline phosphatase (B-ALP) and S P1NP) at 12 weeks of three different doses of ODX (3.0, 6.0 and 9.0 mg/kg ODX).

Full Title of Study: “A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 2018

Detailed Description

Males, diagnosed with CRPC, who fulfil the inclusion criteria and does not have any exclusion criteria, will be asked to participate in the study. The subject will be informed orally and in writing about the study procedures and give written informed consent, prior to study start. At the screening visit the following examinations are performed: Physical examination, medical history and concomitant medication. Heart rate, blood pressure, weight, height, body temperature and respiratory rate are measured. Blood samples are drawn and urine sample is collected. ECG is recorded. Bone scan and diagnostic CT scan are also performed. At the next visit, baseline, the subject is examined physically and heart rate, blood pressure, weight, body temperature and respiratory rate are measured, ECG is recorded, blood samples drawn and urine sample collected. FACT-P and EQ-5D-5L (European Quality of Life – 5 Dimensions with 5 levels) questionnaire are filled out by the subject. Adverse events and concomitant medication is documented and the first dose of the investigational product is given. The subject is surveyed for 3 hours at the hospital. The duration of the study for the individual subject will be approximately 20 weeks from screening to the follow-up visit 2 weeks after the last dose. Each subject will receive 10 doses of investigational product. After the follow-up visit, the subject enters to long-term follow-up phase which lasts approximately 2 years. A Data Monitoring Committee (DMC) will be designated and will be responsible to monitor/review all study related safety data. After review of safety data the DMC will provide recommendation as to whether the dose escalation can proceed as planned according to the protocol.

Interventions

  • Drug: Osteodex
    • formulation: solution for infusion route of administration: intravenous infusion

Arms, Groups and Cohorts

  • Experimental: Osteodex 3.0 mg/kg
    • formulation: solution for infusion route of administration: intravenous infusion
  • Experimental: Osteodex 6.0 mg/kg
    • formulation: solution for infusion route of administration: intravenous infusion
  • Experimental: Osteodex 9.0 mg/kg
    • formulation: solution for infusion route of administration: intravenous infusion

Clinical Trial Outcome Measures

Primary Measures

  • Relative change from baseline in response markers related to bone metabolism (B-ALP and S P1NP).
    • Time Frame: Baseline and 20 weeks of treatment

Secondary Measures

  • Progression free survival, defined as the time from study entry to the date of disease progression or death from any cause.
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
  • Overall survival, defined as the time from randomisation to the date of death from any cause.
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
  • Change from baseline in response markers related to bone metabolism (B-ALP and S P1NP) at each time point sampled (except 12 weeks).
    • Time Frame: Baseline and 20 weeks of treatment
  • Change from baseline in response markers related to bone metabolism (Serum C-Terminal Telopeptide (S-CTX) and osteocalcin) at each time point sampled.
    • Time Frame: Baseline and 20 weeks of treatment
  • Change from baseline in Prostate Specific Antigen (PSA) at each time point sampled.
    • Time Frame: Baseline and 20 weeks of treatment
  • Time to PSA progression
    • Time Frame: Baseline and 20 weeks of treatment
  • Time to ALP progression
    • Time Frame: Baseline and 20 weeks of treatment
  • Time to P1NP progression
    • Time Frame: Baseline and 20 weeks of treatment
  • Time to progression in bone
    • Time Frame: Baseline and 20 weeks of treatment
  • Time to progression in soft tissue
    • Time Frame: Baseline and 20 weeks of treatment
  • Use of analgesics as reported by the patient during treatment and follow-up
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
  • Therapy response based on changes from baseline according to Response Evaluation Criteria In Solid Tumors (RECIST) based on diagnostic CT in patients with measurable soft tissue metastases.
    • Time Frame: Baseline and 20 weeks of treatment
  • Changes from baseline in bone metastasis by means of bone scan at each time point examined.
    • Time Frame: Baseline and 20 weeks of treatment
  • Occurrence of symptomatic skeletal events
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
  • Pain (FACT-P questionnaire)
    • Time Frame: Baseline and 20 weeks of treatment
  • Pain (EQ-5D-5L questionnaire)
    • Time Frame: Baseline and 20 weeks of treatment
  • Quality of life (EQ-5D-5L questionnaire)
    • Time Frame: Baseline and 20 weeks of treatment
  • Incidence, causality and intensity of Adverse Events (AEs)
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks
  • Dose and duration of medications required for the treatment of AEs
    • Time Frame: Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Age ≥18 years at the time of signing the informed consent form 2. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate 3. Evidence of disease progression based on changes in metastatic bone disease (≥2 bone lesions compared to a prior examination) in bone scan and/or other imaging modality AND/OR evidence of PSA progression in the three consecutive determinations at minimum of 1 week intervals 4. Castrate level of serum testosterone ≤1.7 nmol/L 5. Performance status ECOG 0-2 6. Laboratory requirements: Haematology: Neutrophils ≥ 1.5 x 109/l Haemoglobin ≥ 90 g/l Platelets ≥ 100 x 109/l Hepatic function: Total S-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN or ≤ 5 times ULN in patients with known liver metastases Renal function: S-creatinine (S-Cr)≤ 1.5 times ULN 7. No evidence (≤ 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin) 8. Able to adhere to the study visit schedule and other protocol requirements Life expectancy ≥6 months Exclusion Criteria:

1. Concurrent use of other anti-cancer agents or treatments, with the following exception: a stable dose of Luteinizing Hormone-Releasing Hormone (LHRH) agonist/antagonist or polyestradiol phosphate. Washout period: bicalutamide 6 weeks; flutamide 4 weeks; abiraterone / enzalutamide 6 weeks, chemotherapy 4 weeks; Radium-223 4 weeks; Strontium-89 or Samarium-153 6 months. 2. Any treatment modalities involving palliative radiation therapy or major surgery within 4 weeks prior to treatment in this study 3. Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment 4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study 5. Known brain metastases 6. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug 7. Treatment with bisphosphonates or denosumab within 4 weeks prior to first dose of study medication

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • DexTech Medical AB
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Anders Holmberg, MD, Study Director, DexTech Medical AB

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.